What Prothya Biosolutions Netherlands does

Prothya Biosolutions Netherlands B.V. is a privately held European biopharmaceutical company that manufactures plasma-derived medicinal products and operates a Contract Development and Manufacturing Organization (CDMO) business serving global pharmaceutical and biotech partners. Formed in 2021 through the integration of Plasma Industries Belgium (PIBe), with roots in the Belgian Red Cross, and Sanquin Plasma Products (SPP), a former subsidiary of the Sanquin Blood Supply Foundation, the company combines more than 60 years of European plasma processing heritage. Its operational footprint spans four countries with offices and subsidiaries in the Netherlands (Amsterdam, headquarters), Belgium (Brussels), Finland (Espoo), and Hungary (Budapest, opened September 2023), and it employs between 501 and 1,000 people. The company operates as part of the Intas Group, a diversified international biopharmaceutical conglomerate, with an August 2025 agreement under which Intas and Accord would acquire Prothya.

The company produces a branded portfolio of plasma-derived therapies under its own label for immunology and critical care applications, including Nanogam/Optiglobin (immunoglobulin 100 mg/ml for primary and secondary immunodeficiency and neuromuscular disorders such as MMN and CIDP), Cofact (prothrombin complex for anticoagulation reversal and congenital coagulation deficiency), Albuman and Crealb in 40 g/l and 200 g/l concentrations (albumin for blood volume restoration in trauma, burns, and sepsis), and Omniplasma (pooled, Solvent Detergent-treated, prion-reduced plasma from voluntary unpaid Dutch donors, launched in 2013). Core technology centers on advanced plasma protein isolation and fractionation, employing Solvent Detergent treatment effective against lipid-enveloped viruses (HIV, HCV, HBV, West Nile virus), prion-specific affinity chromatography for prion reduction, and sterile filtration. Manufacturing facilities are cGMP-compliant with EMA, FDA, and national authority audit readiness.

Prothya generates revenue through two streams: (1) sale of own-brand plasma-derived medicinal products to healthcare professionals and patients via partner distribution networks reaching hospitals, pharmacies, and clinical chemical laboratories, and (2) CDMO professional services to pharmaceutical and biotech partners covering product and process development, viral safety assessment, formulation development, analytical method pre-validation, and contract manufacturing of plasma intermediates, API material, drug substance, final formulated bulk, and labeled or unlabeled vials. The company self-describes as the largest CDMO partner in the blood plasma industry, with Biotest AG highlighted as a flagship CDMO customer relationship spanning more than a decade. Go-to-market is enterprise field sales to healthcare providers and pharmaceutical partners, supported by a corporate website, dedicated healthcare professional and CDMO portals, careers sites, and a media center. In July 2021, the company acquired ProVen Pharmaceuticals to broaden its product portfolio.

Name

Prothya Biosolutions Netherlands

Legal name

Prothya Biosolutions Netherlands B.V.

Website

https://prothya.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Prothya Biosolutions is a European biopharmaceutical company that manufactures branded plasma-derived medicinal products (immunoglobulins, albumin, prothrombin complex, SD-treated plasma) and operates the largest CDMO in the blood plasma industry, serving pharmaceutical partners and patients with immune deficiencies, coagulation disorders, and critical care needs.

Ownership category

akta.pro rank

Product category

Plasma-derived Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ)

Keywords

• Plasma-derived medicines
• Plasma fractionation
• Contract development manufacturing
• Immunoglobulin therapy
• Critical care biologics

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Plasma-derived Medicinal Products: Manufacturing and sale of own-brand plasma-derived medicinal products including Immunoglobulin (Nanogam/Optiglobin), Albumin (Albuman/Crealb), Prothrombin Complex (Cofact), and pooled SD-treated plasma (Omniplasma) for immunology and critical care applications.
2. CDMO/Contract Manufacturing Services: Providing contract development and manufacturing organization services to pharmaceutical partners including product/process development, contract manufacturing of plasma intermediates, API, drug substance and drug bulk/final products, and plasma operations. Prothya is positioned as the largest CDMO partner in the blood plasma industry.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Prothya Biosolutions uses advanced methods to isolate proteins from blood plasma and convert them into plasma-derived medicinal products under its own brand for immunology and critical care applications. The portfolio includes immunoglobulins, albumin, prothrombin complex, and pooled SD-treated plasma. Beyond its own branded products, the company operates as a Contract Development and Manufacturing Organization (CDMO), offering its infrastructure and expertise to pharmaceutical partners for plasma intermediates, API, drug substance, and finished product manufacturing.

Product overview

Prothya Biosolutions is a plasma-derived medicinal products company offering a portfolio of branded products under its own label for immunology and critical care applications. The core product portfolio includes immunoglobulins (Nanogam/Optiglobin), albumin products (Albuman/Crealb in 40 g/l and 200 g/l concentrations), and prothrombin complex (Cofact). The company also offers pooled, SD-treated plasma (Omniplasma, launched in 2013) with prion reduction technology. Beyond its own branded products, Prothya operates as a Contract Development and Manufacturing Organization (CDMO), providing professional services to industry partners including product/process development, contract manufacturing (API, drug substance, drug bulk and final product), and plasma operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Nanogam / Optiglobin
• Cofact Prothrombin complex product used for anticoagulation therapy when emergency correction of coagulation is required, such as acute hemorrhaging or emergency surgery, or for treatment of patients with congenital coagulation deficiency.
• Albuman 40 g/l Albumin product at 40 g/l concentration used in critical care to restore blood flow in patients suffering significant blood loss after accidents, or for treatment of severe burns or sepsis.
• Albuman 200 g/l / Crealb 200 g/l Albumin product at 200 g/l concentration used in critical care for blood volume regulation and restoration in patients with significant blood loss.
• Omniplasma Pooled, SD (solvent/detergent) treated and prion reduced plasma product made from voluntary and unpaid Dutch donors. One batch consists of approximately 600-1200 donations. Has a constant composition of coagulation factors and other plasma proteins.
• CDMO / Contract Manufacturing Services Contract development and manufacturing organization (CDMO) services for pharmaceutical and biotech partners, including product/process development, contract manufacturing of plasma intermediates, API, drug substance, drug bulk, and final products, and plasma operations. Prothya is positioned as the largest CDMO partner in the blood plasma industry.

Quantifiable outcome

• Prothya has become the largest CDMO partner in the blood plasma industry

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Biotest AGcoreStrategic or Co-development PartnerLong-standing CDMO partnership spanning over a decade. Biotest relies on Prothya for contract manufacturing services enabling production of life-saving products for patients worldwide. Prothya accommodates requests and short-term inquiries, continuously develops services to meet partner needs.
• Intas GroupflagshipStrategic or Co-development PartnerProthya Biosolutions Belgium is part of the Intas Group. The company is entering an exciting phase of growth and transformation with continued investment in manufacturing capabilities, infrastructure, project portfolio, and organizational maturity. Intas & Accord signed agreement to acquire Prothya Biosolutions (August 2025).
• Sanquin Blood Supply FoundationcoreStrategic or Co-development PartnerSanquin Plasma Products (SPP), a former subsidiary of Sanquin Blood Supply Foundation, integrated into Prothya Biosolutions in 2021. Sanquin Blood Bank collects plasma from voluntary unpaid Dutch donors used in Prothya's products including Omniplasma.
• Plasma Industries Belgium (PIBe)coreStrategic or Co-development PartnerPlasma Industries Belgium, with roots in the Belgian Red Cross, integrated with Sanquin Plasma Products in 2021 to form Prothya Biosolutions. This integration combined expertise from both Belgian and Dutch plasma processing traditions.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• CSL Behring: Global leader in plasma-derived therapies and the largest plasma fractionator worldwide, part of CSL Limited. Operates an integrated plasma collection network and broad immunoglobulin, albumin, and specialty product portfolio that competes head-on with Prothya's branded franchises across immunology and critical care.
• Grifols: Spanish multinational plasma therapeutics company with vertically integrated collection centers and a portfolio spanning immunoglobulins, albumin, coagulation factors, and alpha-1 antitrypsin. Competes directly with Prothya across plasma-derived product lines and offers third-party contract manufacturing services analogous to Prothya's CDMO business.
• Takeda Pharmaceutical (Plasma-Derived Therapies): Inherited from the Baxalta/Shire acquisition, Takeda's PDT franchise includes immunoglobulin (Gammagard) and albumin products directly comparable to Prothya's Nanogam and Albuman lines, plus significant CDMO-scale plasma fractionation capacity across global facilities.

Regional players

• GC Pharma: South Korean biopharmaceutical company producing plasma-derived therapeutics including immunoglobulins and albumin, primarily serving Asian markets. Compares to Prothya in product mix and fractionation capabilities, though operating in a different geographic footprint.

Direct peers

• Octapharma: Private Swiss-headquartered plasma fractionator producing immunoglobulins, coagulation factors, and albumin. Prothya's Omniplasma is explicitly described as following a similar SD-treated methodology to Octaplas LG made by Octapharma, making them direct comparables in both pooled plasma and the broader plasma therapeutics space.
• Biotest AG: German plasma therapeutics company marketing immunoglobulins, coagulation factors, and albumin. Biotest is both a direct competitor in plasma-derived products and Prothya's largest disclosed long-term CDMO customer, creating a uniquely comparable hybrid customer/competitor relationship.
• Kedrion Biopharma: Italian-headquartered plasma fractionator with a product portfolio in immunoglobulins, coagulation factors, and albumin, plus a meaningful CDMO business. Comparable to Prothya as a mid-sized European plasma specialist with vertically integrated collection-to-finished-product capabilities.
• Laboratoire Français du Fractionnement et des Biotechnologies (LFB): French plasma fractionator producing immunoglobulins, coagulation factors, and albumin from plasma collected through French blood establishments. Comparable to Prothya as a European national-scale plasma specialist with similar regulatory positioning and product portfolio.

Others

• Sanquin Blood Supply Foundation: Dutch blood bank and former parent of Sanquin Plasma Products (now Prothya). Continues to supply voluntary unpaid donor plasma to Prothya and operates diagnostic and reagent businesses. Treated as a strategic supplier and ecosystem participant rather than a direct competitor.

Emerging players

• China Biologic Products Holdings: Chinese plasma-derived therapeutics manufacturer with a portfolio of human albumin, immunoglobulin, and coagulation products. Comparable in product scope to Prothya though operating predominantly in the Chinese market with different plasma sourcing and regulatory dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prothya

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prothya Biosolutions Netherlands